Reduction intrapulmonary shunts and plasma levels of vascular endothelial growth factor and TNF (Rosuvastatin alleviates experimental hepatopulmonary syndrome through blockade of pulmonary inflammatory angiogenesis via TNF/NF-κB and VEGF/Rho-associated A kinase pathways down-regulation). The gene discussed is VEGFA; the disease is hepatopulmonary syndrome.